The Community Focus Channel on VJHemOnc is an independent medical education platform, supported with funding from Johnson & Johnson (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ESH CML/MPN 2025 | Commonly observed side effects with asciminib and how to manage them
Giuseppe Saglio, MD, University of Turin, Turin, Italy, outlines the commonly observed side effects of asciminib and briefly comments on potential management strategies for these adverse events. Hematological toxicity, particularly thrombocytopenia, is often observed; however, Prof. Saglio highlights that this may be in part due to the biology of the disease. In addition, lipase elevation is typical, as with all tyrosine kinase inhibitors (TKIs). This interview took place at the European School of Haematology (ESH) 4th How to Diagnose and Treat: CML/MPN meeting in Vienna, Austria.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
I think that certainly the most common is represented by hematological toxicity, but we know that hematological toxicity, in particular the decrease of platelet counts, is mainly due to defective normal hematopoiesis. Maybe there is also a direct effect of the drug, but I think that certainly this can represent the problem. I think that in the future, and this is something that we have to start, just the addition of growth factors and also growth factors for platelets like eltrombopag or other drugs, which is commonly done outside registration at the moment, but maybe in the future it will become also one possibility, will overcome this problem...
I think that certainly the most common is represented by hematological toxicity, but we know that hematological toxicity, in particular the decrease of platelet counts, is mainly due to defective normal hematopoiesis. Maybe there is also a direct effect of the drug, but I think that certainly this can represent the problem. I think that in the future, and this is something that we have to start, just the addition of growth factors and also growth factors for platelets like eltrombopag or other drugs, which is commonly done outside registration at the moment, but maybe in the future it will become also one possibility, will overcome this problem.
And the other, I would say, the other problem that we have is certainly some enzyme elevation, which is a lipase elevation, which is a liver enzyme, a little bit of elevation, but this is something that we have with all the different TKIs. And, substantially, I would say that is something that cannot be avoided. So, of course, all drugs always have side effects, but we have to balance which are the advantages and which are the disadvantages that we can have.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
